Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds
    21.
    发明申请
    Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds 审中-公开
    金属肽γ-黑素细胞刺激激素化合物

    公开(公告)号:US20080255033A1

    公开(公告)日:2008-10-16

    申请号:US12136233

    申请日:2008-06-10

    IPC分类号: A61K38/04

    摘要: Metallopeptides with a sequence of a biologically active gamma-melanocyte stimulating hormone sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two and three position to the C-terminus side of the n position, or alternatively is substituted for the residue at any position from the three position to the n position, with a metal ion complexed thereto, with any proline (Pro) residue which is either of the two residues on the immediately adjacent N-terminus side of the inserted or substituent residue comprising a nitrogen atom and sulfur atom available for complexation to a metal ion is substituted with a homolog.

    摘要翻译: 具有长度为n个残基的生物活性γ-黑素细胞刺激激素序列序列的金属肽,其中包含可用于与金属离子络合的氮原子和硫原子的残基被插入到两个和三个位置之间的任何位置, 或者在n位置的任何位置用n位置的任何位置取代残基,其中与其配合的金属离子与任何两个残基中的任一种的脯氨酸(Pro)残基 在包含可与金属离子络合的氮原子和硫原子的插入或取代残基的紧邻N末端侧被同系物取代。

    Knockout identification of target-specific sites in peptides
    23.
    发明授权
    Knockout identification of target-specific sites in peptides 有权
    敲除肽中靶特异性位点的鉴定

    公开(公告)号:US07351690B2

    公开(公告)日:2008-04-01

    申请号:US10769695

    申请日:2004-01-30

    IPC分类号: A61K38/16

    摘要: The invention provides methods for identification and determination of target-specific sites in peptides and proteins, including a method for determining the primary sequence of a secondary structure within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of a peptide or protein. The resulting sequence is complexed with a metal ion thereby forming a metallopeptide. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide(s) which result in significant or substantially decreased or changed binding or functionality are determined to identify the primary sequence involved in such binding or functionality.

    摘要翻译: 本发明提供用于鉴定和确定肽和蛋白质中靶特异性位点的方法,包括确定结合目的靶标的已知亲本多肽内的二级结构的一级序列的方法。 在本发明的一个实施方案中,含有可与金属离子结合的氮原子和硫原子的残基或模拟物连续取代肽或蛋白质的已知一级序列中相邻残基之间或插入其中的单个残基。 所得到的序列与金属离子络合,从而形成金属肽。 然后将所得金属肽用于与感兴趣靶标相关的结合或功能测定,并确定导致显着或显着降低或改变的结合或功能的金属肽,以鉴定涉及这种结合或功能的一级序列。

    Pyrrolidine melanocortin-specific compounds
    24.
    发明授权
    Pyrrolidine melanocortin-specific compounds 有权
    吡咯烷黑皮质素特异性化合物

    公开(公告)号:US07189755B2

    公开(公告)日:2007-03-13

    申请号:US10776657

    申请日:2004-02-10

    IPC分类号: A61K31/4025 C07D207/04

    摘要: Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.

    摘要翻译: 具有以下结构的黑皮质素受体特异性吡咯烷化合物及其立体异构体和药学上可接受的盐,其中R 1,R 2和R 3是 如说明书中所述,优选其中R 3是具有至少一个取代或未取代的苯基或萘基芳环的D-氨基酸,并且其中R 3'任选地进一步包括 胺封端基团或一至三个另外的氨基酸残基,任选具有胺封端基团,该化合物是一种或多种黑皮质素受体的激动剂,拮抗剂或混合激动剂和拮抗剂,并且可用于治疗黑皮质素受体相关 疾病和病症。 还公开了结构(I)化合物的合成方法,含有结构(I)化合物的药物组合物及其使用方法。

    Substituted melanocortin receptor-specific piperazine compounds
    25.
    发明授权
    Substituted melanocortin receptor-specific piperazine compounds 有权
    取代的黑皮质素受体特异性哌嗪化合物

    公开(公告)号:US07709484B1

    公开(公告)日:2010-05-04

    申请号:US11110060

    申请日:2005-04-19

    摘要: A substituted piperazine compound having the structure I: or the structure IX: or an enantomeric, stereoisomeric or diastereomeric form of the foregoing, and pharmaceutically acceptable salts thereof, where J, L, Q, W, A, R6, R7, z and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration, which compounds bind to one or more melanocortin receptors and may be employed in pharmaceutical preparations for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.

    摘要翻译: 其中J,L,Q,W,A,R6,R7,z和y具有结构I或结构IX的取代哌嗪化合物或其前体的烯醇,立体异构体或非对映体形式及其药学上可接受的盐 标记有星号的碳原子可以具有任何立体化学构型,该化合物结合一种或多种黑皮质素受体并可用于治疗一种或多种黑皮质素受体相关病症或病症的药物制剂中 以及使用本发明化合物的方法。

    Piperazine melanocortin-specific compounds
    26.
    发明授权
    Piperazine melanocortin-specific compounds 有权
    哌嗪黑皮质素特异性化合物

    公开(公告)号:US07354923B2

    公开(公告)日:2008-04-08

    申请号:US10762079

    申请日:2004-01-21

    IPC分类号: A61K31/497 C07D403/04

    摘要: Melanocortin receptor-specific piperazine or ketopiperazine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where X is CH2 or C═O, R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group, a second amino acid residue or a second amino acid residue with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.

    摘要翻译: 具有以下结构的黑皮质素受体特异性哌嗪或酮哌嗪化合物及其立体异构体和药学上可接受的盐,其中X为CH 2或CO,R 1,R 2 R 3和R 3 3如说明书中所述,优选其中R 3为具有至少一个取代或未取代的苯基或萘基芳基的D-氨基酸 环,并且其中R 3 3任选地进一步包括胺封端基团,第二氨基酸残基或具有胺封端基团的第二氨基酸残基,所述化合物是激动剂,拮抗剂或混合激动剂和拮抗剂 一种或多种黑皮质素受体,并且可用于治疗黑皮质素受体相关疾病和病症。 还公开了结构(I)化合物的合成方法,含有结构(I)化合物的药物组合物及其使用方法。

    Linear and cyclic melanocortin receptor-specific peptidomimetics
    28.
    发明授权
    Linear and cyclic melanocortin receptor-specific peptidomimetics 有权
    线性和环状黑皮质素受体特异性肽模拟物

    公开(公告)号:US08114844B2

    公开(公告)日:2012-02-14

    申请号:US12244880

    申请日:2008-10-03

    摘要: Linear and cyclic peptidomimetics which bind to one or more melanocortin receptors are provided, which peptidomimetics include at least one ring-constrained amino acid surrogate of formula I: where R1, R2, R3, R4, R5, R6, R7, R8, and y are as defined in the specification, together with methods for synthesizing ring-constrained amino acid surrogates of formula I and peptidomimetics incorporating the same, and methods of use of peptidomimetics in the treatment of various diseases, syndromes and conditions.

    摘要翻译: 提供了结合一种或多种黑皮质素受体的线性和环肽模拟物,其中肽模拟物包括至少一个式I的环受限氨基酸替代物:其中R1,R2,R3,R4,R5,R6,R7,R8和y 以及用于合成式I的环受限制的氨基酸替代物的方法和包含其的肽模拟物的方法,以及使用肽模拟物治疗各种疾病,综合征和病症的方法。

    Linear natriuretic peptide constructs
    30.
    发明授权
    Linear natriuretic peptide constructs 有权
    线性利钠肽构建体

    公开(公告)号:US07795221B2

    公开(公告)日:2010-09-14

    申请号:US11694358

    申请日:2007-03-30

    IPC分类号: A61K38/10

    摘要: Linear constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group covalently bound to a reactive group of at least one of the amino acid residues or surrogates, pharmaceutical compositions including such linear constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.

    摘要翻译: 具有与利尿钠肽受体结合的N末端和C末端并且包括多个氨基酸残基和至少一个式I的氨基酸替代物的线性构建体:其中R,R',Q,Y,W, Z,J,x和n如说明书中所定义,以及任选地至少一个与至少一个氨基酸残基或替代物的反应性基团共价结合的假基团,包括这种线型构建体的药物组合物,以及治疗方法 充血性心力衰竭或其它需要诱导抗高血压,心血管,肾或内分泌作用的综合征或疾病。